1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Alivus Life Sciences Ltd

Alivus Life Sciences Ltd

1,269.00
INR
+11.10
(+0.88%)
48.33EPS
23.88P/E
141.95BMarket Cap
Oct 29Next Earn
Alivus Life Sciences Ltd
NSE:ALIVUS
(National Stock Exchange of India)

Recent

price

1,269.00

P/E

ratio

23.88

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
111.06
121.96
151.92
177.62
167.13
178.31
190.95
204.03
212.16
Revenue per Share
23.89
25.55
28.69
35.63
38.11
38.43
39.63
45.99
48.43
Basic EPS, GAAP
0.08
11.74
26.13
39.6
11.69
23.22
18.39
21.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
10.95
31.5
22.5
- -
5
- -
Dividend per Share
7.19
32.78
61.44
167.66
174.51
190.35
229.92
271.49
- -
Book Value per Share
6.67
32.2
60.79
166.81
173.04
189.14
228.29
269.05
- -
Tangible Book Value per Share
123
123
123
118
123
123
123
123
123
Basic Weighted Avg Shares
13,608
14,943
18,614
20,874
20,478
21,848
23,398
25,042
26,043
Sales/Revenue/Turnover
30.08
29.7
30.18
27.73
29.34
28.48
26.66
28.85
28.89
Operating Margin (%)
193
294
334
379
421
535
606
754
775
Depreciation Expense
2,927
3,131
3,516
4,187
4,670
4,709
4,856
5,645
5,945
Net Income, GAAP
27.53
25.64
25.35
25.88
25.72
25.41
25.76
24.87
24.68
Effective Tax Rate (%)
21.51
20.95
18.89
20.06
22.8
21.55
20.75
22.54
22.83
Profit Margin (%)
-4,497
-1,473
1,776
13,806
13,538
14,772
18,650
21,413
- -
Working Capital
- -
- -
- -
12
171
148
510
488
- -
LT Debt
881
4,017
7,527
20,543
21,382
23,323
28,174
33,321
- -
Total Equity
- -
131.49
71.21
30.23
21.03
20.51
17.68
16.68
- -
Return on Invested Capital (%)
- -
138.01
72.23
31.28
22.18
20.95
18.66
18.16
- -
Return on Capital (%)
- -
127.84
60.91
29.83
22.28
21.07
18.86
18.36
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
80
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
488
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
123
123
Market Capitalization
112,448
119,386
141,948

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
26,494
- -
Cash, Cash Equivalents & STI
- -
7,824
- -
Accounts Receivable, Net
- -
10,730
- -
Inventories
- -
6,919
- -
Total Current Liabilities
- -
5,080
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
80
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
45.03%
18.27%
Free Cash Flow
- -
13.74%
14.65%
Net Income, GAAP
- -
10.17%
16.24%
Sales/Revenue/Turnover
- -
6.21%
7.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,886
5,069
6,418
6,495
23,398
2026
6,018
- -
6,729
6,891
25,042
2027
6,404
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
9.1
7.78
11.18
11.57
39.63
2026
9.91
- -
12.25
13.23
45.99
2027
13.04
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
5
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Alivus Life Sciences Ltd. (ALIVUS.NS) develops, manufactures and supplies select high-value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas including cardiovascular disease, central nervous system disorders, diabetes, pain management, oncology and anti-infectives; its API portfolio encompasses products such as olmesartan, telmisartan, perindopril, sitagliptin, rosuvastatin, mirabegron, zonisamide, atovaquone, cabozantinib and palbociclib; the company also provides contract development and manufacturing organization (CDMO) services, regulatory support, containment solutions and end-to-end development to multinational and specialty pharmaceutical firms. Alivus operates manufacturing facilities in India with R&D centers serving over 70 global markets including North America, Europe, Japan, Latin America, India and the rest of the world (ROW); it supplies high-quality APIs to more than 700 pharmaceutical customers worldwide. Formerly known as Glenmark Life Sciences Limited and incorporated in 2011 with headquarters in Mumbai, Maharashtra, India and registered office in Solapur, Maharashtra, the company originated as the API business unit of Glenmark Pharmaceuticals in 2001 before becoming independently managed. In March 2024, Nirma Limited, a diversified Indian conglomerate, acquired a majority 75% stake, establishing Alivus as its subsidiary and new promoter; the company rebranded from Glenmark Life Sciences to Alivus Life Sciences Limited in December 2024 and January 2025, marking a strategic shift to enhance its global presence in APIs and CDMO; recent developments include the Solapur facility Phase 1 expansion for 200 KL capacity, planned additions of approximately 100 KL in Ankleshwar and 160 KL in Dahej, new CDMO deals announced in January 2024, commercialization of five CDMO projects by late 2025 targeting 50 crore rupees quarterly revenue, and cumulative DMF/CEP filings reaching 586 as of September 2025.